Potential prognostic value in human breast cancer of cytosolic Nme1 protein detection using an original hen specific antibody. by Toulas, C. et al.
Aft'm British Journal of Cancer (1996) 73, 630-635
i> (B) 1996 Stockton Press All rights reserved 0007-0920/96 $12.00
Potential prognostic value in human breast cancer of cytosolic Nmel
protein detection using an original hen specific antibody
C Toulas', J Mihura', C de Balincourt', B Marques', E Marek', G Soula" 2, H Roche' and
G Favrel2
'Claudius Regaud Comprehensive Center, 20-24 rue du Pont St Pierre, 31052 Toulouse Cedex, France; 2Laboratory ofDrug
Targeting Research, JE 175 DRED, Paul Sabatier University, Toulouse, France
Summary The metastasis-suppressor nme gene (also called nm23), first identified in murine melanoma cells,
exists as two forms in human: nmel and nme2. However, only the lack of expression of nmel has been related
to distant metastasis appearance in human breast cancer. The aim of this work was first to raise specific
antibodies to allow the analysis of Nmel and then, with this specific tool, to evaluate the predictive value of
Nmel detection in cytosolic extracts of human breast tumours. We obtained a hen antibody that specifically
reacts with Nmel without any cross-reaction with Nme2. We analysed the expression of the protein in 59
human breast tumours and found a significant relationship between this expression and oestrogen receptor
status (P<0.001). Moreover, Nmel expression is related to metastasis-free survival (P<0.001) and survival of
patients (P<0.001). The determination of Nmel expression in primary tumours using our antibody should be
an interesting predictive test of the metastasis for clinical investigations.
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The metastasis-suppressor gene, nmel was identified in 1988
(Steeg et al., 1988) by differential hybridisation between low
and high metastatic murine melanoma cell lines: the mRNA
expression of this gene was found to be higher in the low
metastatic cell line. In human, the nme gene family consists of
two closely related genes: nmel and nme2, which respectively
code for two different subunits (A and B) of nucleotide
diphosphate kinases (NDP kinases) (Gilles et al., 1991).
These two subunits, which show more than 88% homology,
associate together in different ratios according to tissue
location, to form hexameric NDP kinases. This class of
enzymes is involved in microtubule association (Nickerson
and Wells, 1991) and G-protein regulation (Kimura and
Shimada, 1988) but the precise molecular mechanism
underlying the role of nme genes in metastasis dissemination
is still unclear. The metastasis-suppressor activity of nmel
seems to be correlated more with serine phosphorylation of
Nmel protein (MacDonald et al., 1993) than with kinase
activity (Sastre-Garau et al., 1992). A recent report (Howlett
et al., 1994) suggests that nmel may play an important role in
the differentiation of human breast cancer. Moreover, Postel
et al. (1993) has suggested that the Nme2 protein is a
transcription factor for the c-myc oncogene.
The predictive value of nme detection has been evaluated
by several authors in human tumours. Reduced expression of
nmel has been found in ovarian carcinomas (Mandai et al.,
1994), in hepatocellular carcinoma (Nakayama et al., 1992;
Yamaguchi et al., 1994; Boix et al., 1994), in metastatic
lymph nodes from patients with papillary carcinoma of the
thyroid (Arai et al., 1993) and in metastasis of malignant
melanoma (Xerri et al., 1994). Conflicting results have been
obtained in colorectal tumorigenesis: Yamaguchi (1993)
obtained lower amounts of nmel mRNA and protein in
colorectal tumours associated with liver metastasis than in
those without such metastasis while Myeroff et al. (1993)
showed an increase of the mRNA level in both high- and
low-metastatic potential tumours, suggesting that the activity
of the nme gene could be tissue specific. In breast cancer a
low level of nmel mRNA has been correlated with a high
metastatic potential (Henessy et al., 1991; Bevilacqua et al.,
1989) to a greater extent than nme2 (Stahl et al., 1991).
The nmel gene is frequently affected by loss of
heterozygosity (LOH) (Leone et al., 1991) but nmel LOH
was not uniformly associated with low protein expression and
poor prognosis (Cropp et al., 1994). Studies using antibodies
directed against NDP kinase A have been performed to
measure Nmel protein expression in tumours but, probably
because of the high sequence homology between NDP kinase
A and B, and the poor predictive value of the B form, these
studies produced controversial results (Sawan et al., 1994;
Lacombe et al., 1991). The first aim of the current work was
to raise an antibody that would specifically recognise Nmel
protein without any cross-reaction with Nme2, to allow
specific analysis ofNmel expression. With this tool, we could
then evaluate the predictive value of Nmel expression: for
this, we studied the relationship between Nmel expression
and other prognostic factors such as menopausal status,
tumour size, histological grade, lymph node status, hormone
receptors, cathepsin D expression, pS2, c-erbB-2. We then
related Nmel expression to disease-free survival and overall
survival in patients.
Materials and methods
Normal and tumour tissues
Breast biopsy specimens were obtained from 59 patients with
operable primary breast cancer who entered the Claudius
Regaud Center between August 1989 and November 1990.
The samples, collected after surgical removal, were stored in
liquid nitrogen until use. Four specimens of normal breast
tissue obtained from patients following mammary reduction
were similarly treated.
The patients entering this study met the following criteria:
primary breast cancer, availability of complete clinical,
histological and biological information, no other primary
cancer and no preliminary treatment. Patients underwent
physical examination every 3 months for the first 2 years and
every 6 months thereafter. Post-surgical treatment was
planned according to prognostic factors and included
chemotherapy, hormonetherapy and/or radiotherapy.
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Pathology
Tumour size was recorded as the largest diameter of the
tumour. Modified Scarff, Bloom and Richardson grades
(Contesso et al., 1987) were assigned to all tumours by
scoring tubular formation, nuclear pleomorphism and
mitosis. Lymph node status was sought and histological
examination used to confirm the involvement with tumour
cells. The average number of lymph nodes examined was
15 and 30% of the patients showed no lymph node
invasion.
Synthesis oJ peptide antigen
The peptide sequence of the antigen was designed from the
amino acid sequence of NDP kinase A (Stahl et al., 1991) to
be divergent with the corresponding sequence of NDP kinase
B: the 16 amino acid peptide from glycine 37 to tyrosine 53
of the protein was synthesised by Novabiochem (France),
purified by high-performance liquid chromatography (HPLC)
and coupled to haemocyanine to increase its immunoreactiv-
ity.
Immunisation of the hen and antibody extraction
The hen received a first injection in the peritoneal muscle of
10 pg of haemocyanin-peptide complex dissolved in 500 pl
of complete Freund's adjuvant (Calbiochem, France). Two
identical injections were then given 12 and 20 days later
(Gassmann et al., 1990). The eggs were collected daily and
stored at 4°C until processing. Egg yolk was separated from
the white, carefully washed with deionised water to remove
albumin, diluted in 60 ml of a 3.5% polyethylene glycol
solution (PEG 6000, Pharmacia, France), and centrifuged for
10 min at 14 000 g at 4°C. The supernatant was filtered and
adjusted to 9% PEG 6000; the solution was centrifuged for
10 min at 9000 g at 4°C. The pellet was resuspended in 40 ml
of 12% PEG and centrifuged for 10 min at 9000 g at 4°C.
The final pellet was resuspended in 5 ml of phosphate-
buffered saline (PBS) and stored at -20°C until use. In this
solution, the IgY represented more than 80% of the total
protein extracted and the specific antibody against NDP
kinase A was 50% of the total IgY (Gassmann et al., 1990).
Protein concentration was measured according to the
Bradford technique (Bradford, 1976).
Analysis of antibody specificity
The labelling specificity of the egg yolk antibody was
analysed by Western blot. NDP kinase A and B, purified
as described previously (Gilles et al., 1991), were kindly
provided by Dr Lascu (University of Bordeaux 2, France).
Extraction of cytosols and membranes from tumours
The breast tumour or normal breast tissue was homogenised
in 10 mm Tris buffer pH 7.4 containing 20 mM molybdic
acid, 12 mM monothioglycerol and centrifuged at 105 000 g
for 30 min at 4°C. The supernatant represented the cytosolic
extract. The pellet was resuspended in 5 mM Hepes, 3 mM
EDTA, 1% Triton Xl 00, 4 mM benzamidine, 1 mM DTT
pH 7.4, and centrifuged for 30 min at 105 000 g. This
supernatant was the membrane extract. Protein concentra-
tions were determined using the Bradford technique
(Bradford, 1976) for cytosolic extract and bicinchoninic acid
(Smith et al., 1985) for the membrane extract.
Measurement of oestrogen or progesterone r-ceptors, cathepsin
D and pS2
The amount of hormonal receptors in the cytosolic extracts
was determined using oestrogen receptor and progesterone
receptor EIA kits (Abbott, France). The cathepsin D and pS2
cytosolic protein amounts were quantified using specific kits
(CIS France).
Measurement of the anmount of erbB-2 protein
Total protein (50 ,ug) from membrane extracts were diluted in
10 mM Tris HCl, 150 mM sodium chloride, 0.2% Tween20
pH 8 (TBST) and spotted onto nitrocellulose membrane
(0.2 Mm Biorad) under vacuum (Dot Blot system, Biorad,
France). The membrane was then incubated at room
temperature in TBST containing 1% lyophilised milk
powder for 90 min and then for 1 h with the same solution
containing the monoclonal antibody c-neu Ab3 (Oncogene
Science, France) at 10 pg ml-'. After three successive washes
in TBST the nitrocellulose membrane was incubated in TBST
containing 0.75 pg ml-' of peroxidase-conjugated goat anti-
mouse antibody (Tebu, France) and washed again three times
with TBST. After incubation in the ECL system (Amersham,
France), the membrane was exposed for 5 s to Hyperfilm MP
(Amersham, France). The film was scanned using a
densitometer (Performance, Sebia, France). Variable
amounts (from 10 pg to 60 ,Ig) of protein extracted from
MCF 7 membranes under the same conditions as the
tumours, were loaded onto the same membrane. The signal
was quantified using the densitometer and the calibration
curve was then drawn. The amount of ErbB-2 protein
contained in tumours was determined from this curve and
expressed in arbitrary units determined as equivalent pg
MCF 7 membrane protein per pg of tumour protein loaded.
Western blot analysis of Nmiel
Total cytosolic protein (60 jig) from each sample and I jig of
pure NDP kinase (Sigma, France) were loaded on a 15%
polyacrylamide gel and electrophoresed at 150 V as described
by Laemmli (1970). The gel was equilibrated in transfer
buffer (480 mM Tris pH 8, 390 mM glycine, 0.5% sodium
dodecyl sulphate (SDS), 25% methanol) for 10 min at room
temperature. The transfer was then performed on a 0.2pm
nitrocellulose membrane at 250 mA for 2 h in the transfer
buffer. The membrane was incubated in TBST containing 10%
lyophilised milk powder for 90 min, then in the same solution
containing extracted anti-Nmel IgY (20 pg protein ml-') for
1 h. After three successive washes in TBST the membrane
was incubated in TBST containing 1% milk and rabbit anti-
chicken IgY peroxydase conjugates (Sigma, France) at a final
dilution of 1 :4000 for 1 h. Three washes were performed in
TBST and the antigen was detected using the ECl system as
previously described. The limit of detection was 200 ng of
pure NDP kinase A (data not shown). The autoradiographs
were scanned and the results expressed as positive if the scan
could detect a band corresponding to a molecular weight of
18 kDa, and negative in the other cases. The pure NDP
kinase (5 jg) loaded on the gel was used as an internal
standard to avoid variations due to different exposures from
one gel to another.
Statistical analy,sis
The association of Nmel expression with other discrete
clinicobiological variables was assessed by chi-square
analysis. The relationships between Nmel expression and
cathepsin D, pS2 and c-erbB-2 were analysed as continuous
variables using the Student's t-test. Disease-related death for
specific survival and metastasis for metastasis-free survival
were scored as events with censoring of other patients at the
time of last follow-up. Survival curves were calculated by the
method of Kaplan and Meier. Univariate analyses were
performed with the log-rank test.
Results
Antibody specificity
The aim of this work was to obtain an antibody able to react
specifically with Nmel without any cross-reaction with the
Nme2 form. Because of the high homology of thie amino acid
sequence (more than 88%) that exists between these twoNmel expression in human breast tumours
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proteins, we decided to immunise the animals with a synthetic
peptide whose sequence is localised in a region of weak
homology. This 16 amino acid peptide of Nmel is located
from glycine 37 to tyrosine 53 and represents less than 50%
of sequence homology with the same region of Nme2.
We first tested the specificity of this antibody by Western
blot analysis. As shown in Figure 1, Nmel antibody was able
to detect pure NDP kinase A whereas it did not react with
pure NDP kinase B. Control IgY did not reveal any signal
(data not shown).
Expression of Nmel in normal and tumour tissues
The expression of Nmel in cytosolic extracts from normal
breast tissues and tumours was then analysed. The Nmel
antibody revealed a band corresponding to the molecular
weight of NDP kinase A (18 kDa) (Figure 2) in breast
tumours. This band was not present when the antibody was
first incubated with 10 jug of peptide coupled to haemocyanin
(Figure 2). No 18 kDa form of Nmel could be detected in
normal breast tissue (data not shown). We then analysed the
expression of Nme in 59 human breast tumours by scanning
the 18 kDa band on the Western blot. Our results are
presented as 'Nmel +' if the scan could detect a 18 kDa band
and 'Nmel -' in the other cases.
Relationship between Nmel expression and other prognostic
factors
We analysed the relationships that might exist between Nmel
expression and the other prognostic factors listed in Table I.
No significant difference was detected between the expression
of Nmel and menopausal status, nodal invasion or tumour
size (Table I). Concerning the histological grade, 74% of
well-differentiated tumours (grades 1 and 2) expressed Nmel
but the relationship was not significant (P = 7.2%) (Table I).
A significant difference was noted according to oestrogen
receptor status (ER): around 71% of ER-negative tumours
did not express Nmel whereas 81% of ER-positive tumours
expressed Nmel (P<0.001). Progesterone receptor (PR)-
positive tumours preferentially expressed Nmel (74%)
compared with PR-negative ones (50%) but the relationship
was not significant (Table I). A possible relationship between
Nmel and tumour hormone dependence was tested by
analysing the pS2 protein expression level in Nmel +
tumours vs Nmel - (Table II). No significant difference
could be observed in the pS2 protein level between Nmel +
tumours and Nmel - tumours. Similar results were obtained
when comparing Nme 1 expression with the amount of
cathepsin D and with erbB-2 expression: 17% of tumours
showed an overexpression of the ErbB-2 protein level (higher
than 30 units). However, no significant difference in ErbB-2
expression level was observed between Nmel- and Nmel +
tumours (Table II).
Relationship between Nmel status, disease-free survival and
overall survival
Of the 59 patients entering this study, 14 have developed
metastasis during the 50 months following surgery, and 12
died from cancer. Median follow-up was 42 months.
Univariate analysis did not show any relationship between
metastasis-free survival or specific survival and histological
grade, lymph node invasion, hormone receptors, cathepsin D
or ErbB-2. It confirmed the predictive value of tumour size
(P<0.01) for specific survival and revealed that Nmel
expression was significantly associated with longer metasta-
sis-free survival (P<0.001) (Figure 3) and to overall survival
(P<0.001) (Figure 4).
Discussion
The results published by Steeg (1988) or Henessy (1991)
suggested that nmel gene expression measured by mRNA
analysis is related to the metastasis potential of human breast
cancer. To analyse the potentialities of the tumour metastasis
Table I Relationship between Nmel expression and prognostic
factors as discrete variables
Tumour andpatient
characteristics Nmel- Nmel + P
Nodal status
Negative 7 13 NS
Positive 13 26
Tumour grade
I or 2 9 27 NS
3 11 12
Tumour size
<2cm 4 13 NS
>2cm 15 25
Menopausal status
Premenopausal 3 18 NS
Post-menopausal 9 23
Oestrogen receptor status
Negative 12 5 <0.001
Positive 8 34
Progesterone receptor status
Negative 10 10 NS
Positive 10 29
Statistical analysis was performed as described in Materials and
methods. NS, non-significant relationship.
18 kDa
Figure 1 Analysis of the hen antibody specificity: the Western
blot analysis was performed on 4,ug of pure NDP Kinase B (lane
1) and 4jig of pure NDP Kinase A (lane 2) as described in
Materials and methods.
1 13 11 A
18 kDa
Figure 2 Nme expression in tumour tissues. The analysis was
performed as described in Materials and methods, using 60 ,ug of
cytosol from tumour tissues expressing Nme I (lane 1) or not
(lane 2) and pure Nme I protein (lane 3). Preincubation of the
antibody with 10 jMg of antigen before Western blot analysis is
shown in lane 4.
Table II Relationship between Nmel expression and prognostic
factors as continuous variable
Tumour marker Nmel- Nmel + P
Cathepsin D level
Mean 48.2 42.2
s.d. 36.6 22.7 NS
n 20 38
pS2 level
Mean 11.7 15.0
s.d. 17.2 18.7 NS
n 20 38
ErbB-2 level
Mean 17.9 19.4
s.d. 23.3 26.9 NS
n 15 27
Statistical analysis was performed as described in Materials and
methods. NS, non-significant relationship.co 0-
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Figure 3 Metastasis-free survival curve according to Nmel
status: Nmel -, no band detectable at 18 kDa; NmelI+, a band
detected by scan densitometer. The curve was calculated
according to the Kaplan-Meier method and statistical analysis
was performed as described in Materials and methods.
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Figure 4 Specific survival curves according to Nmel status:
Nmel -, no band detectable at 18 kDa; Nmel +, a band detected
by scan densitometer. The curve was calculated according to the
Kaplan-Meier method and statistical analysis was performed as
described in Materials and methods.
gene to predict metastasis outcome we raised an antibody
against an Nmel protein. Instead of immunising animals with
the whole Nmel protein a 16 amino acid peptide, derived
from a region of the protein that represents a weak sequence
homology, was injected into hens. The immunisation
produced an antibody that specifically reacted with Nme 1
without any cross-reaction with the Nme2 form. This highly
specific tool was then used to analyse Nme 1 protein
expression in human breast tumours by Western blotting.
In our study, Nmel was not detected in any of the four
normal breast tissues tested. Immunohistochemical studies of
Nmel have given conflicting data concerning the staining of
normal cells: in the study by Hiriyama et al. (1991) cells of
normal acini and glands in the breast tissue generally could
be weakly stained or not stained at all; Sastre-Gareau
(1992), using a polyclonal anti-NDP kinase A, observed no
or moderate staining of normal lobules and ducts; Simpson
et al. (1994) reported that the percentage of Nm23 reactivity
of lobular or ductal carcinoma in situ was greater than that
of adjacent normal tissue. Other workers (Barnes et al.,
1991; Tokunaga et al., 1993; Royds et al., 1993), using
different polyclonal antibodies, detected staining in normal
breast. All the antibodies used in these studies recognised
Nmel expression in human breast tumours
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both Nme1 and Nme2 and so detected the expression of
both proteins in normal breast. That our antibody does not
cross-react with Nme2 would explain the lower expression
seen in our study; the level of Nmel expression in normal
breast cytosol is probably lower than the sensitivity limit of
our hen antibody.
Our work analysed the possible relationships between
Nmel expression and other prognostic factors. No significant
relationship was demonstrated either with age, menopausal
status, tumour size, or lymph node status. Even if 74% of
well-differentiated tumours expressed Nme1, no significant
relationship could be detected between histological grade and
Nmel expression (P=7%). Studies by Henessy et al. (1991),
Bevilacqua et al. (1989) and Royds et al. (1993) related Nmel
negative expression to histological grade and to worsening
invasive ductal carcinoma grade. It could be supposed that
by using a larger population than examined in our study, we
would have revealed a link between Scarff-Bloom-Richard-
son (SBR) grade and Nmel expression. On the other hand, a
positive relationship between Nmel expression and hormonal
receptors has been shown in our study but this relationship
was only significant for the oestrogen receptor (P<0.001).
Several workers (Adami et al., 1985; Reiner, 1990) have
related the amount of oestrogen receptor to the differentia-
tion status of the tumour. Our data also suggest that nmel
could be related to differentiation state of the tumour. This is
in agreement with the recent observations of Howlett et al.
(1994), who showed that nmel-transfected cell lines in culture
with a reconstituted basement membrane presented char-
acteristics of breast differentiation. Even if these results do
not imply that the nme]l gene universally controls breast
differentiation, it may be one important gene in the process
of differentiation.
Like the progesterone receptor, the expression of pS2
protein is oestrogen dependent (Brown et al., 1984) and is
predictive of a favourable response to endocrine therapy in
human breast cancer (Henry et al., 1991). In our work, no
significant relationship was observed between Nmel expres-
sion and the pS2 protein level. These data and the absence of
a link between Nmel expression and progesterone status
would indicate that Nme1 is not related to hormone
dependent tumour status.
The c-erbB-2 oncogene, which encodes for a transmem-
brane glycoprotein with high homology with epidermal
growth factor receptor, is amplified in 15-30% of breast
cancer. This overexpression has been found to be related to
an increase in the proliferative activity of the tumour and by
some authors to a shorter survival (Wright et al., 1989;
Tandon et al., 1989; Rilke et al., 1991). More recently, an
overexpression of c-erbB-2 has been associated to the
response to chemotherapy (Muss et al., 1994). A significant
relationship between the expression of c-erbB-2 and the
mRNA level of nmel has been shown in ovarian carcinomas
(Mandai et al., 1994); this relationship was also observed by
immunohistochemical staining of sections for nme products
and c-erbB-2. On the contrary, Slamon (1991) reported that
human breast and ovarian carcinoma cell lines transfected
with HER2/neu exhibited reduced nme mRNA levels. In our
population, an overexpression of c-erbB-2 was observed in
17% of tumours but no significant relationship between c-
erbB-2 and Nmel expression could be demonstrated.
Furthermore, Nmel expression was independent of another
metastasis predictive factor, cathepsin D levels, suggesting
that the metastasis process involving Nmel protein could be
different from that of cathepsin D.
We have described here highly significant relationships
between Nmel expression and metastasis-free survival
(P<0.001) and specific survival (P<0.001). These results
obtained at the level of protein expression using our antibody
are in agreement with several studies analysing nmel mRNA
levels in breast cancer (Henessy et al., 1991) and in other
locations (Arai et al., 1993). Although this approach needs to
be confirmed by a larger study, it underlines the interesting
role of specifically detecting cytosolic nmel for the prediction
of metastasis outcome in breast cancer.
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